S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
S&P 500   4,464.05
DOW   35,281.40
QQQ   366.24
Biden and House Democrats hope to make curbing 'junk fees' a winning issue in 2024
Laser breakthrough could send stock soaring 2,467% (Ad)
Yes, inflation is down. No, the Inflation Reduction Act doesn't deserve the credit
Stock market today: Asia follows Wall Street lower after US data revive fears about rate hike
Laser breakthrough could send stock soaring 2,467% (Ad)
Illinois governor signs ban on firearms advertising allegedly marketed to kids and militants
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
US Steel rejects a $7.3 billion offer from rival Cleveland-Cliffs; considers alternatives
Don't expect quick fixes in 'red-teaming' of AI models. Security was an afterthought
Top-Rated StocksTop-Rated
NYSE:BDX

Becton, Dickinson and Company (BDX) Stock Forecast, Price & News

$282.31
+5.08 (+1.83%)
(As of 08/11/2023 08:47 PM ET)
Compare
Today's Range
$276.11
▼
$282.53
50-Day Range
$249.52
▼
$283.85
52-Week Range
$215.90
▼
$287.32
Volume
1.33 million shs
Average Volume
1.17 million shs
Market Capitalization
$81.90 billion
P/E Ratio
51.24
Dividend Yield
1.29%
Price Target
$284.89
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Becton, Dickinson and Company MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
0.9% Upside
$284.89 Price Target
Short Interest
Healthy
0.99% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.45
Upright™ Environmental Score
News Sentiment
0.34mentions of Becton, Dickinson and Company in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$360,269 Sold Last Quarter
Proj. Earnings Growth
10.56%
From $12.22 to $13.51 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

173rd out of 987 stocks

Surgical & Medical Instruments Industry

27th out of 98 stocks

See Top Rated MarketRank™ Stocks Here

BDX stock logo

About Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Price History

BDX Stock News Headlines

August 12, 2023 | americanbankingnews.com
Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $360,269.00 in Stock
August 11, 2023 | finance.yahoo.com
Q2 2023 Accelerate Diagnostics Inc Earnings Call
August 14, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
August 9, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) PT Raised to $303.00
August 9, 2023 | americanbankingnews.com
Q1 2024 Earnings Forecast for Becton, Dickinson and Company (NYSE:BDX) Issued By William Blair
August 9, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) Price Target Increased to $303.00 by Analysts at Barclays
August 8, 2023 | msn.com
Barclays Maintains Becton, Dickinson And (BDX) Overweight Recommendation
August 8, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) Given New $310.00 Price Target at Morgan Stanley
August 14, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
August 8, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $310.00 at Morgan Stanley
August 7, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) Lifted to Buy at StockNews.com
August 7, 2023 | americanbankingnews.com
Becton, Dickinson and Company (NYSE:BDX) Receives Average Recommendation of "Moderate Buy" from Analysts
August 5, 2023 | msn.com
Morgan Stanley Maintains Becton, Dickinson And (BDX) Overweight Recommendation
August 4, 2023 | nasdaq.com
Raymond James Maintains Becton, Dickinson And (BDX) Outperform Recommendation
August 3, 2023 | finance.yahoo.com
Becton Dickinson (BDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
August 3, 2023 | msn.com
Becton Dickinson Clocks Strong Q2 Sales From Medical Devices, Raises Annual Outlook
August 3, 2023 | msn.com
Becton, Dickinson falls despite Q3 beat amid COVID headwinds
August 3, 2023 | finance.yahoo.com
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
August 3, 2023 | seekingalpha.com
Becton, Dickinson and Company 2023 Q3 - Results - Earnings Call Presentation
August 3, 2023 | reuters.com
Becton Dickinson beats quarterly profit estimates on strong medical device sales
August 3, 2023 | markets.businessinsider.com
Becton, Dickinson and Company Q3 Profit Increases, beats estimates
August 2, 2023 | finance.yahoo.com
Is a Surprise Coming for BD (BDX) This Earnings Season?
July 24, 2023 | investopedia.com
Becton Dickinson Shares Jump After FDA Decision on Its Infusion System
July 24, 2023 | finance.yahoo.com
Is Becton, Dickinson and Co (BDX) Stock Modestly Overvalued? An In-Depth Analysis
July 24, 2023 | msn.com
Raymond James Upgrades Becton, Dickinson And (BDX)
July 24, 2023 | barrons.com
Becton Dickinson Leads Gainers in the S&P 500
July 24, 2023 | reuters.com
Becton Dickinson shares hit record high after US FDA clears return of drug infusion system
See More Headlines
Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Becton, Dickinson and Company and its competitors with MarketBeat's FREE daily newsletter.

BDX Company Calendar

Ex-Dividend for 6/30 Dividend
6/08/2023
Dividend Payable
6/30/2023
Last Earnings
8/03/2023
Today
8/13/2023
Ex-Dividend for 9/29 Dividend
9/07/2023
Dividend Payable
9/29/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/09/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSE:BDX
CUSIP
07588710
CIK
10795
Web
www.bd.com
Phone
(201) 847-6800
Fax
201-847-6475
Employees
77,000
Year Founded
1897

Price Target and Rating

Average Stock Price Forecast
$284.89
High Stock Price Forecast
$310.00
Low Stock Price Forecast
$250.00
Forecasted Upside/Downside
+0.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.51
Trailing P/E Ratio
51.24
Forward P/E Ratio
23.10
P/E Growth
2.34
Net Income
$1.78 billion
Net Margins
8.73%
Pretax Margin
9.46%
Return on Equity
13.24%
Return on Assets
6.35%

Debt

Debt-to-Equity Ratio
0.58
Current Ratio
1.25
Quick Ratio
0.73

Sales & Book Value

Annual Sales
$18.87 billion
Price / Sales
4.34
Cash Flow
$19.56 per share
Price / Cash Flow
14.43
Book Value
$89.40 per share
Price / Book
3.16

Miscellaneous

Outstanding Shares
290,110,000
Free Float
289,210,000
Market Cap
$81.90 billion
Optionable
Optionable
Beta
0.57

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Thomas E. Polen Jr.Mr. Thomas E. Polen Jr. (Age 50)
    Pres, CEO & Chairman
    Comp: $3.93M
  • Mr. Christopher J. DelOreficeMr. Christopher J. DelOrefice (Age 52)
    Exec. VP & CFO
    Comp: $1.99M
  • Ms. Shana Carol Neal (Age 56)
    Exec. VP & Chief People Officer
    Comp: $1.44M
  • Mr. David B. HickeyMr. David B. Hickey (Age 60)
    Exec. VP & Pres of Life Sciences Segment
    Comp: $1.41M
  • Mr. Thomas J. SpoerelMr. Thomas J. Spoerel (Age 45)
    Sr. VP, Controller & Chief Accounting Officer
  • Ms. Elizabeth McCombs (Age 47)
    Exec. VP & Chief Technology Officer
  • Dr. Joseph M. Smith F.A.C.C
    M.D., Ph.D., Sr. VP, Chief Scientific Officer & Co-Chair of Scientific Advisory Board
  • Ms. Denise Fleming
    Exec. VP of Technology & Global Services and Chief Information Officer
  • Ms. Francesca M. DeMartino
    Sr. VP & Head of Investor Relations
  • Ms. Michelle Quinn (Age 54)
    Exec. VP & Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BDX Stock - Frequently Asked Questions

Should I buy or sell Becton, Dickinson and Company stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BDX shares.
View BDX analyst ratings or view top-rated stocks.

What is Becton, Dickinson and Company's stock price forecast for 2023?

9 brokers have issued twelve-month price targets for Becton, Dickinson and Company's shares. Their BDX share price forecasts range from $250.00 to $310.00. On average, they anticipate the company's share price to reach $284.89 in the next twelve months. This suggests a possible upside of 0.9% from the stock's current price.
View analysts price targets for BDX or view top-rated stocks among Wall Street analysts.

How have BDX shares performed in 2023?

Becton, Dickinson and Company's stock was trading at $254.30 at the beginning of the year. Since then, BDX stock has increased by 11.0% and is now trading at $282.31.
View the best growth stocks for 2023 here.

Are investors shorting Becton, Dickinson and Company?

Becton, Dickinson and Company saw a increase in short interest in July. As of July 31st, there was short interest totaling 2,860,000 shares, an increase of 23.8% from the July 15th total of 2,310,000 shares. Based on an average daily trading volume, of 1,250,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 1.0% of the shares of the stock are sold short.
View Becton, Dickinson and Company's Short Interest.

When is Becton, Dickinson and Company's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our BDX earnings forecast.

How were Becton, Dickinson and Company's earnings last quarter?

Becton, Dickinson and Company (NYSE:BDX) released its quarterly earnings results on Thursday, August, 3rd. The medical instruments supplier reported $2.96 EPS for the quarter, beating the consensus estimate of $2.89 by $0.07. The medical instruments supplier had revenue of $4.88 billion for the quarter, compared to analysts' expectations of $4.84 billion. Becton, Dickinson and Company had a net margin of 8.73% and a trailing twelve-month return on equity of 13.24%. Becton, Dickinson and Company's revenue was up 5.1% compared to the same quarter last year. During the same quarter last year, the business posted $2.66 earnings per share.
Read the conference call transcript.

How often does Becton, Dickinson and Company pay dividends? What is the dividend yield for Becton, Dickinson and Company?

Becton, Dickinson and Company declared a quarterly dividend on Tuesday, July 25th. Stockholders of record on Friday, September 8th will be given a dividend of $0.91 per share on Friday, September 29th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.29%. The ex-dividend date of this dividend is Thursday, September 7th.
Read our dividend analysis for BDX.

What ETFs hold Becton, Dickinson and Company's stock?

ETFs with the largest weight of Becton, Dickinson and Company (NYSE:BDX) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Kovitz Core Equity ETF (EQTY), Subversive Mental Health ETF (SANE), ClearBridge Focus Value ESG ETF (CFCV), ClearBridge Dividend Strategy ESG ETF (YLDE), Simplify Health Care ETF (PINK), T. Rowe Price Equity Income ETF (TEQI) and First Trust Indxx Medical Devices ETF (MDEV).

Is Becton, Dickinson and Company a good dividend stock?

Becton, Dickinson and Company (NYSE:BDX) pays an annual dividend of $3.64 per share and currently has a dividend yield of 1.29%. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 66.06%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, BDX will have a dividend payout ratio of 26.94% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for BDX.

How will Becton, Dickinson and Company's stock buyback program work?

Becton, Dickinson and Company declared that its Board of Directors has approved a share repurchase plan on Thursday, November 4th 2021, which permits the company to repurchase 10,000,000 shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are generally a sign that the company's management believes its shares are undervalued.

What guidance has Becton, Dickinson and Company issued on next quarter's earnings?

Becton, Dickinson and Company updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $12.10-$12.32 for the period, compared to the consensus earnings per share estimate of $12.22. The company issued revenue guidance of $19.30 billion-$19.30 billion, compared to the consensus revenue estimate of $19.29 billion.

What is Tom Polen's approval rating as Becton, Dickinson and Company's CEO?

136 employees have rated Becton, Dickinson and Company Chief Executive Officer Tom Polen on Glassdoor.com. Tom Polen has an approval rating of 91% among the company's employees. This puts Tom Polen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Becton, Dickinson and Company own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Becton, Dickinson and Company investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), AT&T (T), NVIDIA (NVDA), Walt Disney (DIS), Abbott Laboratories (ABT), Intel (INTC), Verizon Communications (VZ), Cisco Systems (CSCO) and CVS Health (CVS).

What is Becton, Dickinson and Company's stock symbol?

Becton, Dickinson and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BDX."

Who are Becton, Dickinson and Company's major shareholders?

Becton, Dickinson and Company's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.82%), Bank Julius Baer & Co. Ltd Zurich (2.44%), Geode Capital Management LLC (1.77%), JPMorgan Chase & Co. (1.28%), Bank of New York Mellon Corp (1.28%) and Clearbridge Investments LLC (1.05%). Insiders that own company stock include Alexandre Conroy, Betty D Larson, Claire Fraser, David Hickey, James C Lim, Michael David Garrison, Rebecca W Rimel, Rebecca W Rimel, Richard Byrd, Roland Goette, Samrat S Khichi, Thomas E Polen Jr, Thomas J Spoerel and Thomas J Spoerel.
View institutional ownership trends.

How do I buy shares of Becton, Dickinson and Company?

Shares of BDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Becton, Dickinson and Company's stock price today?

One share of BDX stock can currently be purchased for approximately $282.31.

How much money does Becton, Dickinson and Company make?

Becton, Dickinson and Company (NYSE:BDX) has a market capitalization of $81.90 billion and generates $18.87 billion in revenue each year. The medical instruments supplier earns $1.78 billion in net income (profit) each year or $5.51 on an earnings per share basis.

How many employees does Becton, Dickinson and Company have?

The company employs 77,000 workers across the globe.

Does Becton, Dickinson and Company have any subsidiaries?
The following companies are subsidiares of Becton, Dickinson and Company: Accuri Cytometers, Accuri Cytometers Inc., Alverix Inc, Alverix Inc., Atto Bioscience Inc, BD Holding S. de R.L. de C.V., BD Infection Prevention BV, BD Kiestra BV, BD Kiestra Total Lab Automation, BD Rapid Diagnostic (Suzhou) Co. Ltd., BD San Luis Potosi S.A. de C.V., BD Switzerland Sarl, BD Ventures LLC, BD West Africa Limited, BDX INO LLC, Bard (Thailand) Limited, Bard ASDI Inc., Bard Access Systems Inc., Bard Acquisition Sub Inc., Bard Australia Pty. Limited, Bard Benelux N.V., Bard Brachytherapy Inc., Bard Brasil Indústria e Comércio de Produtos Para a Saúde Ltda., Bard Canada Inc., Bard Chile S.p.A., Bard Czech Republic s.r.o., Bard Devices Inc., Bard Dublin ITC Limited, Bard EMEA Finance Center Sp.z o.o., Bard European Distribution Center N.V., Bard Finance B.V. & Co. KG., Bard Financial Services Ltd., Bard Finland OY, Bard France S.A.S., Bard Global Holdings I LLC, Bard Global Holdings II LLC, Bard Global Holdings III LLC, Bard Healthcare Inc., Bard Healthcare Science (Shanghai) Limited, Bard Hellas S.A., Bard Holding SAS, Bard Holdings Limited, Bard Holdings Netherlands B.V., Bard Hong Kong Limited, Bard IP Holdings Inc., Bard India Healthcare Pvt. Ltd., Bard International Holdings B.V., Bard International Inc., Bard Istanbul Healthcare Limited Company, Bard Korea Ltd., Bard Limited, Bard MRL Acquisition Corp., Bard Malaysia Healthcare Sdn. Bhd., Bard Medica SA, Bard Medical Devices (Beijing) Co. Ltd., Bard Medical R&D (Shanghai) Co. Ltd., Bard Medical SA (Proprietary) Limited, Bard Mexico Realty S. de R.L. de C.V., Bard Norden AB, Bard Norway AS, Bard Pacific Health Care Company Ltd., Bard Peripheral Vascular Inc., Bard Poland Sp. z.o.o., Bard Productos Plasticos e Medicos Ltda., Bard Reynosa S.A. de C.V., Bard S.r.l., Bard Sdn. Bhd., Bard Shannon Limited, Bard Singapore Private Limited, Bard Sourcing Office Singapore Pte. Ltd., Bard Sweden AB, Bard UK Newco Limited, Bard de Espana S.A., Becton Dickinson (Gibraltar) Holdings Ltd., Becton Dickinson (Gibraltar) Limited, Becton Dickinson (Gibraltar) Management Limited, Becton Dickinson (Mauritius) Limited, Becton Dickinson (Pty) Ltd., Becton Dickinson (Thailand) Limited, Becton Dickinson A.G., Becton Dickinson A/S, Becton Dickinson Argentina S.R.L., Becton Dickinson Asia Holdings Ltd., Becton Dickinson Asia Limited, Becton Dickinson Austria GmbH, Becton Dickinson Austria Holdings GmbH, Becton Dickinson B.V., Becton Dickinson B.V. Saudi Limited Company, Becton Dickinson Benelux N.V., Becton Dickinson Biosciences Systems and Reagents Inc., Becton Dickinson Canada Inc., Becton Dickinson Caribe Ltd., Becton Dickinson Croatia d.o.o., Becton Dickinson Czechia s.r.o., Becton Dickinson Dispensing Belgium BVBA, Becton Dickinson Dispensing Denmark A/S, Becton Dickinson Dispensing France SAS, Becton Dickinson Dispensing Ireland Limited, Becton Dickinson Dispensing Norway, Becton Dickinson Dispensing Spain S.L.U., Becton Dickinson Dispensing UK Ltd., Becton Dickinson Distribution Center N.V., Becton Dickinson East Africa Ltd., Becton Dickinson Euro Finance Sarl, Becton Dickinson Europe Holdings S.A.S., Becton Dickinson France S.A.S., Becton Dickinson GSA Beteilgungs GmbH, Becton Dickinson Global Holdings I Inc., Becton Dickinson Global Holdings II LLC, Becton Dickinson Global Holdings IV LLC, Becton Dickinson Global Holdings V LLC, Becton Dickinson Global Holdings VII LLC, Becton Dickinson Global Holdings VIII LLC, Becton Dickinson Global Services Centre Sdn. Bhd, Becton Dickinson GmbH, Becton Dickinson Guatemala S.A., Becton Dickinson Hellas S.A., Becton Dickinson Holdings Limited, Becton Dickinson Holdings Ltd., Becton Dickinson Holdings Pte Ltd., Becton Dickinson Hungary Kft., Becton Dickinson India Private Limited, Becton Dickinson Industrias Cirurgicas Ltda., Becton Dickinson Infusion Therapy AB, Becton Dickinson Infusion Therapy Holdings UK Limited, Becton Dickinson Infusion Therapy Systems Inc., Becton Dickinson Infusion Therapy Systems Inc. S.A. de C.V., Becton Dickinson Infusion Therapy UK, Becton Dickinson Insulin Syringe Ltd., Becton Dickinson International Holdings II Pte Ltd., Becton Dickinson International Holdings III Pte Ltd., Becton Dickinson International Holdings Pte Ltd., Becton Dickinson Israel Ltd., Becton Dickinson Italia S.p.A., Becton Dickinson Ithalat Ihracat Limited Sirketi, Becton Dickinson Korea Holding Inc., Becton Dickinson Korea Ltd., Becton Dickinson Ltd., Becton Dickinson Luxembourg Finance S.a.r.L., Becton Dickinson Luxembourg Global Holdings Sarl, Becton Dickinson Luxembourg Holdings II S.a.r.L, Becton Dickinson Luxembourg Holdings III S.a.r.L, Becton Dickinson Luxembourg Holdings V S.a.r.L., Becton Dickinson Malaysia Inc., Becton Dickinson Management GmbH & Co. KG, Becton Dickinson Matrex Holdings Inc., Becton Dickinson Medical (S) Pte Ltd., Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Becton Dickinson Medical Devices (Suzhou) Co. Ltd., Becton Dickinson Medical Products Pte. Ltd., Becton Dickinson Medical Technology (Jiangsu) Co. Ltd., Becton Dickinson Netherlands Global Holdings II C.V., Becton Dickinson Netherlands Holdings B.V., Becton Dickinson Netherlands Holdings II B.V., Becton Dickinson Norway AS, Becton Dickinson O.Y., Becton Dickinson Overseas Services Ltd., Becton Dickinson Pakistan (Pvt) Ltd., Becton Dickinson Penel Limited, Becton Dickinson Philippines Inc., Becton Dickinson Polska Sp.z.o.o., Becton Dickinson Portugal Unipessoal Lda., Becton Dickinson Pty. Ltd., Becton Dickinson Research Centre Ireland Limited, Becton Dickinson Rowa Germany GmbH, Becton Dickinson Rowa Italy Srl, Becton Dickinson S.A., Becton Dickinson Sample Collection GmbH, Becton Dickinson Scot Financing L.L.P., Becton Dickinson Scot Financing L.P., Becton Dickinson Sdn. Bhd., Becton Dickinson Slovakia s.r.o., Becton Dickinson Sweden AB, Becton Dickinson Sweden Holdings AB, Becton Dickinson Switzerland Global Holdings SarL, Becton Dickinson Technology Campus India, Becton Dickinson U.K. Limited, Becton Dickinson UK Financing I Limited, Becton Dickinson UK Financing II Limited, Becton Dickinson Venezuela C.A., Becton Dickinson Venture LLC, Becton Dickinson Verwaltungs GmbH, Becton Dickinson Vostok LLC, Becton Dickinson Worldwide Investments Sa.r.L., Becton Dickinson Zambia Limited, Becton Dickinson and Company Ltd., Becton Dickinson de Colombia Ltda., Becton Dickinson de Mexico S.A. de C.V., Becton Dickinson del Uruguay S.A., Bee IT Solutions, Benex Ltd., Biometric Imaging, Bridger Biomed Inc., C. R. Bard (Portugal) - Produtos e Artigos Medicos e Farmaceuticos, C. R. Bard Do Brasil Productos Medicos Ltda., C. R. Bard GmbH, C. R. Bard Inc., C. R. Bard Netherlands Sales B.V., C.R. Bard Inc, CME America LLC, CME Ltd., CME Medical (UK) Limited, CME UK (Holdings) Limited, CRISI Medical Systems, CRISI Medical Systems Inc., Caesarea Medical Electronics, Cardal II LLC, Care Fusion Development Private Limited, CareFusion (Barbados) SrL, CareFusion (Shanghai) Commercial and Trading Co. Limited, CareFusion 213 LLC, CareFusion 2200 Inc., CareFusion 2201 Inc., CareFusion 302 LLC, CareFusion 303 Inc., CareFusion Asia (HK) Limited, CareFusion Corporation, CareFusion Corporation., CareFusion D.R. 203 Ltd., CareFusion France 309 S.A.S., CareFusion Israel 330 Ltd., CareFusion Italy 312 S.p.A., CareFusion Manufacturing LLC, CareFusion Mexico 215 S.A. de C.V., CareFusion Netherlands 328 B.V., CareFusion Netherlands 503 B.V., CareFusion Netherlands 504 B.V., CareFusion Netherlands Financing 283 C.V., CareFusion Resources LLC, CareFusion S.A. 319 (Proprietary) Limited, CareFusion Solutions LLC, CareFusion U.K. 244 Limited, CareFusion U.K. 305 Limited, CareFusion U.K. 306 Limited, Carmel Pharma AB, Carmel Pharma Inc, Cato Software Solutions, Cell Analysis Systems Inc, Cellular Research, Cellular Research Inc., Clearstream Technologies Group Limited, Clearstream Technologies Limited, Clontech Laboratories Inc, Corporativo BD de Mexico S. de R.L. de C.V., Critical Device Corporation, Cubex, Cytognos, Cytopeia Inc, DLD (Bermuda) Ltd., DVL Acquisition Sub Inc., Davol Inc., Davol International Limited, Davol Surgical Innovations S.A. de C.V., Difco Laboratories Incorporated, Distribuidora BD Mexico S.A. de C.V., Dutch American Manufacturers (D.A.M.) B.V., Dymax Corporation, Embo Medical Limited, Enturia de Mexico S. de R.L. de C.V., Enturican Inc., FJ International Inc., FlowCardia Inc., FlowCardia LLC, FlowJo LLC, Franklin Lakes Enterprises L.L.C., GSL Solutions, Gamer Lasertechnik GmbH, GenCell Biosystems, GenCell Biosystems Ltd., GeneOhm Sciences Canada ULC, GeneOhm Sciences Inc, Gentest Corporation, Gesco International Inc., Gesco International LLC, Glentech Inc, HandyLab Inc, HandyLab Inc., IBD Holdings LLC, Iontophoretics Corporation, JoHome LLC, Kabushiki Kaisha Medicon (Medicon Inc.), Liberator Health and Education Services Inc., Liberator Health and Wellness Inc., Liberator Medical Holdings Inc., Liberator Medical Supply Inc., Limited Liability Company Bard Rus, Loma Vista Medical Inc., Loma Vista Medical LLC, Luther Medical Products Inc, Lutonix Inc., Med-Design Corporation, Med-Design Investment Holdings Inc., Med-Safe Systems Inc, Med-Safe Systems Inc., MedChem Products Inc., Medafor Inc., Medegen LLC, Medinservice.com Inc., Medivance Inc., NAT Diagnostics Inc., NAT Diagnostics Inc., NOW Medical Distribution Inc., NOW Medical Distribution LLC, Navarre Biomedical LLC, Navarre Biomedical Ltd., Neomend Inc., Nippon Becton Dickinson Company Ltd., Omega Biosystems Incorporated, P.R.C. (Isialys) Societe a responsabilitie limitee, PT Becton Dickinson Indonesia, PharMingen, PharMingen., Plasso Technology Ltd, PreAnalytiX GmbH, Pristine Access Technologies Inc., ProSeed Inc., Procesos para Esterilizacion S.A. de C.V., Productos Bard de Mexico S.A. de C.V., Productos Para el Cuidado de la Salud S.A. de C.V., Puls Medical Devices AS LC, PureWick Corporation, Roberts Laboratories Inc., Rochester Medical Corporation, Rochester Medical Ltd., Saf-T-Med Inc, Safety Syringes Inc., Scanwell Health Inc., Sendal S.L.U., SenoRx Inc., SenoRx LLC, Shield Healthcare Centers Inc., Sirigen Group Limited, Sirigen II Limited, Sirigen Inc., Sistemas Médicos ALARIS S.A. de C.V., Specialized Cooperative Corporation, Specialized Health Products Inc., Specialized Health Products International Inc., Specialized Health Products International LLC, Staged Diabetes Management LLC, Straub Medical AG, Straub Medical AG, Surgical Site Solutions Inc., TVA Medical Inc, TVA Medical Inc., Tepha Inc, Tepha Inc., Tissuemed Ltd., Tri-County Medical & Ostomy Supplies Inc., TriPath Imaging Inc., Tru-Fit Marketing Corporation, Vas-Cath Incorporated, Vascular Pathways Inc., Velano Vascular, Velano Vascular Inc., Venclose Inc., Venetec International Inc., Venetec International LLC, Visitec, Y-Med Inc., Y-Med LLC, and ZebraSci Inc..
Read More
How can I contact Becton, Dickinson and Company?

Becton, Dickinson and Company's mailing address is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. The official website for the company is www.bd.com. The medical instruments supplier can be reached via phone at (201) 847-6800, via email at investor.relations@bd.com, or via fax at 201-847-6475.

This page (NYSE:BDX) was last updated on 8/14/2023 by MarketBeat.com Staff

My Account -